- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
- HIV infection may shorten a person’s life expectancy by about 5 years
- Moderna CEO: The COVID-19 vaccine will be updated every year like the iPhone 1 dose per year
- UK approved the world’s first vaccine for COVID-19 Omicron
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
New hypoglycemic drug: Dulaglutide | only once a week
- A highly infectious disease that has been extinct for more than 40 years has appeared in New York
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Omicron new variant BA.2.75 has stronger infectivity than BA.4 and BA.5?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
New hypoglycemic drug: Dulaglutide | only once a week.
The new hypoglycemic drug dulaglycotide protects the kidneys and reduces weight and is beneficial to the cardiovascular system. Only once a week.
In recent years, with the continuous in-depth research on type 2 diabetes, many new hypoglycemic drugs have also appeared on the market. Glucagon-like peptide-1 (GLP-1) receptor agonists are one of the most eye-catching ones. class.
Exenatide, liraglutide, risnaglutide and benaglutide have been marketed in some countries in succession of these drugs, but their families have not stopped multiplying.
Recently, the newly born new member of this family, dulaglycotide, has also entered the 2020 edition of the National Medical Insurance Catalog, and its market price has also fallen sharply, which can be described as a good news for patients with type 2 diabetes. Dulaglutide is a newly launched GLP-1 receptor agonist in some countries in 2019.
Compared with other hypoglycemic drugs, what advantages does it have? Today we will take stock.
Introduction to Dulaglutide
Dulaglutide is a new type of glucagon-like peptide-1 (GLP-1) analog that only needs to be injected once a week.
Through DNA recombination technology, it is produced by CHO cells, which can reduce blood sugar and improve the function of pancreatic β cells.
Pharmacological effects of delaying gastric emptying and increasing satiety.
Indications: Suitable for blood sugar control of adult type 2 diabetes patients: Single-drug therapy is used for patients with poor blood sugar control only by diet control and exercise.
Combination therapy is used on the basis of diet control and exercise, to receive metformin, or sulfonylureas, or metformin combined with sulfonylureas to treat adults with type 2 diabetes who still have poor blood sugar control.
Dulaglutide acts on GLP-1 receptors, promotes insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, and can delay gastric emptying, reducing food intake through central appetite suppression.
In other words, it is through indirect promotion of insulin secretion to achieve hypoglycemic effect in many ways, so it also has a certain protective effect on islet cells and can slow down islet cell failure.
But its hypoglycemic effect is stronger. Studies have shown that dulaglutide has a greater reduction in glycated hemoglobin (HbA1c) than exenatide and sitagliptin, similar to liraglutide.
At the same time, the unique mechanism of action of dulaglutide also makes it less likely to cause hypoglycemia when used alone, and is safer.
Dulaglutide has kidney protection
Renal function damage is one of the complications of diabetes. Patients with diabetic nephropathy often have proteinuria and decreased glomerular filtration rate.
Studies have found that dulaglycotide can reduce the risk of composite renal endpoint by about 15%, and the incidence of new massive proteinuria and continuous decline in glomerular filtration rate is significantly reduced, indicating that long-term use can significantly reduce the incidence of renal damage.
Dulaglutide can effectively control weight
Everyone knows that one of the side effects of insulin injection is weight gain, which is not conducive to blood sugar control.
Dulaglutide can delay gastric emptying and suppress appetite to prevent patients from overeating.
The results of a 52-week phase III clinical trial found that dulaglutide reduced the average weight of patients by 1.47 kg at 26 weeks, while the average weight of patients in the insulin glargine group increased by 0.97 kg.
Obviously Glycopeptides are more able to control weight.
Dulaglutide has good cardiovascular protection
Many diabetic patients often have cardiovascular diseases such as hypertension and coronary heart disease, and are more prone to adverse cardiovascular events.
Dulaglutide has a good cardiovascular protective effect.
Studies have found that dulaglutide can significantly reduce the risk of adverse cardiovascular events by 12%, of which the risk of non-fatal stroke is significantly reduced by 24%.
In addition, it can also reduce blood triglycerides and cholesterol levels, and improve patients with non-alcoholic fatty liver. Therefore, it is more suitable for type 2 diabetes patients with atherosclerotic cardiovascular disease.
Dulaglutide is more convenient to use and more compliant
Dulaglutide only needs to be injected subcutaneously once a week.
Compared with insulin that needs to be injected several times a day, it undoubtedly greatly improves the patient’s compliance and avoids subcutaneous fat atrophy and induration at the injection site after repeated injections.
In short, the new hypoglycemic drug dulaglycotide can be said to combine the advantages of other types of hypoglycemic drugs.
With its entry into the national medical insurance catalog and the sharp decline in prices, it will surely rank among the clinical first-line hypoglycemic drugs in the near future. , It is worth your attention.
New hypoglycemic drug: Dulaglutide | only once a week
(source:internet, reference only)